Immunohistochemical evaluation of p53, FHIT, and IGF2 gene expression in esophageal cancer

Diseases of the Esophagus

Volumn 25, Issue 1, 2012, Pages 81-87

  Chava, S ^a   Mohan, V ^c   Shetty, P J ^a   Manolla, M L ^a   Vaidya, S ^a   Khan, I A ^a,b   Waseem, G L ^b   Boddala, P ^b   Ahuja, Y R ^a   Hasan, Q ^a,b  

^a AC Guards ^*  (India)

^b Kamineni Hospitals   (India)

^c Department of Genetics   (India)

Author keywords

ADC; Dysplasia; Esophageal pathology; Immunohistochemistry; SCC

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 2;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DYSPLASIA; ESOPHAGUS CANCER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SQUAMOUS EPITHELIUM;

ACID ANHYDRIDE HYDROLASES; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, SQUAMOUS CELL; EPITHELIUM; ESOPHAGEAL NEOPLASMS; ESOPHAGUS; FEMALE; GENE EXPRESSION; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR II; MALE; MIDDLE AGED; NEOPLASM PROTEINS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84855654342     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2011.01213.x     Document Type: Article

References (43)

1. Croce C M. Role of chromosome translocations in human neoplasia. Cell 1987; 49: 155-6.
2. Soloman E, Borrow J, Goddart A. Chromosome aberrations and cancer. Science 1991; 254: 1153-60.
3. Pisani P, Parkin D M, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18-29.
4. Parkin D M, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
5. Jemal A, Centre M M, Desantis C, Ward E M. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010; 19: 1887. DOI.10.1158/1055-9965.
6. Mohan V, Ponnala S, Reddy H M etal. Chromosome 11 aneusomy in esophageal cancers and precancerous lesions - an early event in neoplastic transformation: an interphase fluorescence in situ hybridization study from south India. World J Gastroenterol 2007; 13: 503-8.
7. Srivastava A, Hornick J L, Li X etal. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus. Am J Gastroenterol 2007; 102: 483-93.
8. Shimizu Y, Yoshida T, Kato M etal. Low-grade dysplasia component in early invasive squamous cell carcinoma of the esophagus. J Gastroenterol Hepatol 2010; 25: 314-8.
9. Micev M, Cosić-Micev M. Pathology and pathobiology of the oesophageal carcinoma. Acta Chir Iugosl 2010; 57: 15-26.
10. Shimada Y, Imamura M, Watanabe G etal. Prognostic factors of oesophageal squamous cell carcinoma from the perspective of molecular biology. Br J Cancer 1999; 80: 1281-8.
11. Levine A J, Momand J, Finlay C A. The p53 tumour suppressor gene. Nature 1991; 351: 453-6.
12. Masuda N, Kato H, Nakajima T etal. Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Sci 2003; 94: 612-17.
13. Zeng Z S, Sarkis A S, Zhang Z F etal. p53 nuclear overexpression: an independent predictor of survival in lymph node-positive colorectal cancer patients. J Clin Oncol 1994; 12: 2043-50.
14. Shibagaki I, Shimada Y, Wagata T, Ikenaga M, Imamura M, Ishizaki K. Allelotype analysis of esophageal squamous cell carcinoma. Cancer Res 1994; 54: 2996-3000.
15. Mori T, Yanagisawa A, Kato Y etal. Accumulation of genetic alterations during esophageal carcinogenesis. Hum Mol Genet 1994; 3: 1969-71.
16. Mori M, Mimori K, Shiraishi T etal. Altered expression of FHIT in carcinoma and precarcinomatous lesions of the esophagus. Cancer Res 2000; 60: 1177-82.
17. Movva S, Sambasivan V, Vattam K, Radha S, Ahuja Y R, Hasan Q. Relevance of insulin-like growth factor 2 in the etiopathophysiology of diabetic nephropathy: possible roles of phosphatase and tensin homolog on chromosome 10 and secreted protein acidic and rich in cysteine as regulators of repair. J Diabetes 2009; 1: 118-24.
18. Ries L A G, Eisner M P, Kosary C L etal. (eds). SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute, 2004.
19. Sant M, Aareleid T, Berrino F etal. EUROCARE Working Group. EUROCARE-3: survival of cancer patients diagnosed 1990-94 - results and commentary. Ann Oncol 2003; 14: 61-118.
20. Coggi G, Bosari S, Roncalli M etal. p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations. Cancer 1997; 79: 425-32.
21. Takano Y, Shiota G, Kawasaki H. Analysis of genomic imprinting of insulin-like growth factor 2 in colorectal cancer. Oncology 2000; 59: 210-6.
22. Shetty P J, Movva S, Pasupuleti N etal. Regulation of IGF2 transcript and protein expression by altered methylation in breast cancer. Cancer Res Clin Oncol 2011; 137: 339-45. DOI: 10.1007/s00432-010-0890-z.
23. Zhou J, Zhao L Q, Xiong M M etal. Gene expression profiles at different stages of human esophageal squamous cell carcinoma. World J Gastroenterol 2003; 9: 9-15.
24. Butsch J, Christein J D, Millikan K. Prognostic factors relating to esophageal cancer. Minerva Chir 2002; 57: 789-94.
25. Levine A J, Perry M E, Chang A etal. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
26. Kawamura T, Goseki N, Koike M, Takizawa T, Endo M. Acceleration of proliferative activity of esophageal squamous cell carcinoma with invasion beyond the mucosa: immunohistochemical analysis of Ki-67 and p53 antigen in relation to histopathologic findings. Cancer 1996; 77: 843-49.
27. Thor A D, Moore D H II, Edgerton S M etal. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-55.
28. Joypaul B V, Hopwood D, Newman E L etal. The prognostic significance of the accumulation of p53 tumour-suppressor gene protein in gastric adenocarcinoma. Br J Cancer 1994; 69: 943-46.
29. Puglisi F, Di Loreto C, Panizzo R etal. Expression of p53 and bcl-2 and response to preoperative chemotherapy and radiotherapy for locally advanced squamous cell carcinoma of the oesophagus. J Clin Pathol 1996; 49: 456-59.
30. Aloia T A, Harpole D H Jr, Reed C E etal. Tumor marker expression is predictive of survival in patients with esophageal cancer. Ann Thorac Surg 2001; 72: 859-66.
31. Gaur D, Arora S, Mathur M, Nath N, Chattopadhaya T K, Ralhan R. High prevalence of p53 gene alterations and protein overexpression in human esophageal cancer: correlation with dietary risk factors in India. Clin Cancer Res 1997; 3: 2129-36.
32. Gui-Bin Q, Cheng-Long H, Ren-Chao J, Chang-Sheng S, Yan W, Yun-Jie W. Overexpression of p53 and its risk factors in esophageal cancer in urban areas of Xi'an. World J Gastroenterol 1998; 4: 57-60.
33. Wigler M H, Parsons R, Druck T etal. Loss of heterozygosity at the familial RCC t(3;8) locus in most clear cell renal carcinomas. Cancer Res 1995; 55: 5348-53.
34. Kastury K, Baffa R, Druck T etal. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res 1996; 56: 978-83.
35. Naylor S L, Johnson B E, Minna J D, Sakaguchi A Y. Loss of heterozygosity of chromosome 3p markers in small cell lung cancer. Nature 1987; 329: 451-54.
36. Hibi K, Takahashi T, Yamakawa K etal. Three distinct regions involved in 3p deletions in human lung cancer. Oncogene 1992; 7: 445-9.
37. Huebner K, Hadaczek P, Siprashvili Z, Druck T, Croce C M. The FHIT gene, a multiple tumor suppressor gene encompassing the carcinogen sensitive chromosome fragile site, FRA3B. Biochim Biophys Acta 1997; 1332: 65-70.
38. Vasavi M, Kiran V, RaviShankar B, Prabhakar B, Ahuja Y R, Hasan Q. Microsatellite Instability analysis and its correlation with hMLH1 repair gene hypermethylation status in esophageal pathologies including cancers. Cancer Biomark 2010; 7: 1-10. DOI.10.3233/CBM-2009-0135.
39. Yu H, Rohan T. Role of the insulin-like growth factor family in cancer development and progression. J Natl Cancer Inst 2000; 92: 1472-89.
40. Ravenel J D, Broman K W, Perlman E J etal. Loss of imprinting of insulin-like growth factor-II (IGF2) gene in distinguishing specific biologic subtypes of Wilms' tumor. J Natl Cancer Inst 2001; 93: 1698-703.
41. Rosen N, Yee D, Lippman M E, Paik S, Cullen K J. Insulin-like growth factors in human breast cancer. Breast Cancer Res Treat 1991; 18 (Suppl 1): 55-62.
42. Nishizaki M, Sasaki J, Fang B etal. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells. Cancer Res 2004; 64: 5745-52.
43. Vogelstein B, Lane S, Levine A J. Surfing the p53 network. Nature 2001; 408: 307-10.